SCHEMBL25946388

SCHEMBL25946388

CC(=O)c1ccc(Cl)nc1-n1nc(Cl)cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPK1 P28482 2/20 0.35
TSHR P16473 1/20 0.35
NPY5R Q15761 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
MAPT P10636 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HTT P42858 1/20 0.33
USP2 O75604 1/20 0.33
CASP1 P29466 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25942572 0.90 HSD17B10 (0.50) MEN1CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL25943104 0.87 MEN1 (0.36) MEN1CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL25946382 0.85 MEN1 (0.35) MEN1CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL25318477 0.84 MEN1 (0.37) MEN1CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL30508578 0.84 MEN1 (0.37) MEN1CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL25943085 0.83 BAZ2B (0.47) MEN1KMT2AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL30508644 0.83 BAZ2B (0.47) MEN1KMT2AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL25942985 0.82 TSHR (0.42) KMT2ASMN1; SMN2ALDH1A1L3MBTL1TSHR
SCHEMBL25946384 0.81 ALDH1A1 (0.33) MEN1CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL31153160 0.77 MEN1 (0.39) MEN1CYP2C9CYP2C19KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466258-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 EP disclosed
US-20240383875-A1 Benzimidazole Pyridine Derivatives HOFFMANN-LA ROCHE INC. (US) 2024-11-21 US disclosed
CN-118591534-A Novel benzimidazole pyridine derivatives 豪夫迈·罗氏有限公司 2024-09-03 CN disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 WO disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383875-A1 Benzimidazole Pyridine Derivatives H1-3, H1-2, H1-4 MEN1 1114/4885CYP2C9 120/4885CYP2C19 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.